<DOC>
	<DOCNO>NCT00655343</DOCNO>
	<brief_summary>The study aim evaluate influence anti-T-lymphocyte globulin ATG-Fresenius S give pre-transplant addition standard GvHD prophylaxis cyclosporine A short course methotrexate respect efficacy safety .</brief_summary>
	<brief_title>Acute Graft-Versus-Host Disease ( aGvHD ) Prophylaxis With ATG-Fresenius Matched Unrelated Donor-Stem Cell Transplantation ( MUD-SCT )</brief_title>
	<detailed_description>To assess efficacy ATG-FRESENIUS S addition standard therapy ( cyclosporine A / methotrexate ) respect early treatment failure define occurrence severe acute GvHD grade III-IV early mortality within 100 day post transplantation compare standard therapy alone . All patient receive myeloablative therapy . Recommended regimen : For patient ALL : fractionate TBI ( 8-12 Gy ) plus cyclophosphamide ( 1-2 x 60 mg/kg ) [ etoposide/melfalan also allow ] . For indication : either TBI ( 8-12 Gy ) busulfan ( per o 14-16 mg/kg b.w . equivalent IV administration ) plus cyclophosphamide ( 1-2 x 60 mg/kg ) thiotepa ≥ 15 mg/kg BCNU ≥ 300 mg/m2 . Conditioning regimen may differ centre centre ; centre decides constant ( disease specific ) regimen ( ) throughout whole study period . Standard GvHD prophylaxis consist cyclosporine A ( target trough level ≥ 200 ng/ml start day -1 day +100 ) short course methotrexate ( 15 mg/m2 day +1 , 10 mg/m2 day +3 , +6 +11 ) .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Participation patient simultaneous diagnostic comprehensive therapeutical trial certain entity allow . Patients 1860 year age ; Patients suffer one follow disease : AML : 1st complete remission ( CR1 ) beyond 1st remission ( CR2 , CR3 ) , relapse , remission ( primary refractory , induction failure ) ; ALL : 1st complete remission ( CR1 ) beyond 1st remission ( CR2 , CR3 ) , relapse , remission ( primary refractory , induction failure ) ; MDS , transplantation medically indicate : RA ( poor risk factor classify International Prognostic Scoring System MDS ) , RARS , RAEB , RAEBt , CMML ; CML : beyond 1st chronic phase ( CP1 ) : accelerate phase , blast crisis , chronic phase ( CP2 , CP3 ) ; OMF , transplantation medically indicate : Osteomyelofibrosis ; Patients designate undergo allogeneic bone marrow transplantation allogeneic peripheral blood stem cell transplantation ; Patients HLAA , B ( DNAbased , 2 digit ) , HLADRB1 , DQB1 ( DNAbased 4 digit ) match ( 8 8 allele ) unrelated donor ; serological typing require Patients Karnofsky Performance Score ( KPS ) : &gt; 60 % ; Patients underwent obligatory screening examination ( special examination within last 4 week ) ; Patients give write informed consent participate study . Patients significant cardiac ( e.g . ejection fraction &lt; 50 % ) , pulmonary ( e.g . FEV1 &lt; 50 % ) , renal ( e.g . creatinine &gt; 1.5 mg/dl ) , metabolic ( e.g . bilirubin &gt; 2.0 mg/dl ) and/or CNS disease , currently uncontrolled treatment , may interfere completion study ; Patients bacterial , viral , fungal infection adequate antimicrobial control ; Patients know serum hepatitis carrier Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody , know positive result test HIV antibody ; Patients additional concurrent previous malignant disease ; Patients know hypersensitivity rabbit immunoglobulin antibody past patient history know allergy substance chemically relate study medication ; Pregnant ( βHCG test ) lactate woman ; Patients formerly underwent transplantation include previous autologous transplant ; Patients communicate reliably investigator likely cope requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>GvHD</keyword>
	<keyword>aGvHD prophylaxis</keyword>
	<keyword>Matched unrelated donor</keyword>
	<keyword>ATG</keyword>
	<keyword>SCT</keyword>
	<keyword>BMT</keyword>
	<keyword>polyclonal antibody</keyword>
	<keyword>GvHD prophylaxis patient ALL , AML , CML , MDS , OMF</keyword>
	<keyword>Patients allogeneic BM PBSC transplantation</keyword>
	<keyword>Patients match unrelated donor</keyword>
</DOC>